{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:43:46Z","timestamp":1789559026487,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1209,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1093\/annonc\/mdw400","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T12:07:29Z","timestamp":1486123649000},"page":"v83-v90","source":"Crossref","is-referenced-by-count":190,"special_numbering":"S5","title":["Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw400_bb0010","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(15)00155-6","article-title":"Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)","volume":"2","author":"Mounier","year":"2015","journal-title":"Lancet Haematol"},{"issue":"Suppl. 5","key":"10.1093\/annonc\/mdw400_bb0015","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0020","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0025","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma\u2014the Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw400_bb0035","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0040","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3324\/haematol.2013.095257","article-title":"The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium","volume":"99","author":"Sander","year":"2014","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw400_bb0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0060","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-C\u00e9ligny","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0065","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0070","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw400_bb0075","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0080","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0085","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisolone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0090","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0095","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0100","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw400_bb0105","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw400_bb0110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw400_bb0115","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0120","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","volume":"31","author":"Vitolo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0125","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0135","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0140","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.509.509","article-title":"Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Salles","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.508.508","article-title":"Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: results of the randomized phase III trial SAKK 35\/03","volume":"122","author":"Taverna","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0150","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab-tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0155","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.369.369","volume":"122","author":"Lopez-Guillermo","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0160","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.419.419","volume":"122","author":"Hiddemann","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0165","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0170","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw400_bb0175","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0180","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw400_bb0185","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw400_bb0190","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0195","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw400_bb0200","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K&dgr; inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw400_bb0205","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1093\/annonc\/mdw400_bb0210","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2012-05-429514","article-title":"Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement","volume":"120","author":"Louissaint","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw400_bb0215","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel\u2014an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdw400_bb0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/suppl_5\/v83\/6679871\/mdw400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T03:33:38Z","timestamp":1582169618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419316606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":43,"alternative-id":["S0923753419316606"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw400","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}